Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 312 articles:
HTML format



Single Articles


    March 2024
  1. MANOS K, Churilov L, Grigg A, Di Ciaccio P, et al
    Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
    Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407.
    PubMed     Abstract available


  2. BAPTISTA P, Aguiar E, Fonseca E, Pinto R, et al
    Intravascular large B-cell lymphoma presenting with haemophagocytic syndrome.
    Br J Haematol. 2024 Mar 12. doi: 10.1111/bjh.19350.
    PubMed    


  3. LI X, Gao F, Meng X, Zhang X, et al
    Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
    Br J Haematol. 2024 Mar 6. doi: 10.1111/bjh.19393.
    PubMed     Abstract available


  4. NGUYEN PC, Nguyen T, Wilson C, Tiong IS, et al
    Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
    Br J Haematol. 2024;204:910-920.
    PubMed     Abstract available


  5. AL-MASHHADI AL, Jakobsen LH, Brown P, Gang AO, et al
    Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
    Br J Haematol. 2024;204:839-848.
    PubMed     Abstract available


    February 2024
  6. BISHTON MJ, Crooks CJ, Card TR, West J, et al
    Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
    Br J Haematol. 2024 Feb 29. doi: 10.1111/bjh.19371.
    PubMed     Abstract available


  7. YE P, Cheng Y, Lian J, Tong H, et al
    Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19367.
    PubMed     Abstract available


  8. STEPANISHYNA Y, Manni M, Civallero M, Shokun N, et al
    Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352.
    PubMed     Abstract available


  9. FLORA DR, Parsons SK, Liu N, Yu KS, et al
    Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19307.
    PubMed     Abstract available


  10. VOGELSBERG A, Harland L, Borgmann V, Otto F, et al
    Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19335.
    PubMed     Abstract available


  11. BEDNARSKA K, Chowdhury R, Tobin JWD, Swain F, et al
    Epstein-Barr virus-associated lymphomas decoded.
    Br J Haematol. 2024;204:415-433.
    PubMed     Abstract available


  12. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    PubMed     Abstract available


  13. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    PubMed     Abstract available


  14. PELLICCIA S, Rogges E, Cardoni A, Lopez G, et al
    The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Br J Haematol. 2024;204:534-547.
    PubMed     Abstract available


    January 2024
  15. LUEDERSEN J, Stadt UZ, Richter J, Oschlies I, et al
    Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
    Br J Haematol. 2024 Jan 26. doi: 10.1111/bjh.19308.
    PubMed     Abstract available


  16. YANG P, Cai M, Cao Y, Fan S, et al
    Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
    Br J Haematol. 2024 Jan 25. doi: 10.1111/bjh.19317.
    PubMed     Abstract available


  17. ABEYAKOON C, Gregory GP
    New standards of care for treatment of diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Jan 22. doi: 10.1111/bjh.19295.
    PubMed     Abstract available


  18. FOX CP, Chaganti S, McIlroy G, Barrington SF, et al
    The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2024 Jan 21. doi: 10.1111/bjh.19273.
    PubMed    


  19. LIAPIS K, Misidou C, Spanoudakis E, Kotsianidis I, et al
    Concurrent visceral leishmaniasis and diffuse large B-cell lymphoma of the bone marrow.
    Br J Haematol. 2024 Jan 7. doi: 10.1111/bjh.19283.
    PubMed    


  20. WALEWSKA R, Eyre TA, Barrington S, Brady J, et al
    Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
    Br J Haematol. 2024;204:86-107.
    PubMed    


  21. VISCO C
    Letting the mantle out of the bag.
    Br J Haematol. 2024;204:11-13.
    PubMed     Abstract available


  22. KHWAJA J, Vos JMI, Pluimers TE, Japzon N, et al
    Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
    Br J Haematol. 2024;204:177-185.
    PubMed     Abstract available


  23. DODERO A, Bramanti S, Di Trani M, Pennisi M, et al
    Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Br J Haematol. 2024;204:151-159.
    PubMed     Abstract available


    December 2023
  24. BAECH J, Husby S, Trab T, Kragholm K, et al
    Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
    Br J Haematol. 2023 Dec 28. doi: 10.1111/bjh.19272.
    PubMed     Abstract available


  25. MOTOMURA Y, Yoshifuji K, Tachibana T, Takase H, et al
    Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
    Br J Haematol. 2023 Dec 22. doi: 10.1111/bjh.19266.
    PubMed     Abstract available


  26. TOTARO A, Calafiore AM, Sacra C, Magnano D, et al
    Huge right atrial mass in mantle cell lymphoma.
    Br J Haematol. 2023 Dec 21. doi: 10.1111/bjh.19258.
    PubMed    


  27. JIN X, Zhou W, Jiang H, Chen Z, et al
    A case of a large number of Reed-Sternberg cells in pleural fluid following treatment of classical Hodgkin lymphoma.
    Br J Haematol. 2023 Dec 20. doi: 10.1111/bjh.19260.
    PubMed    


  28. MASRONI MSB, Leong SM, Cheng H, Lim GS, et al
    miR-101-5p modulation of CD47 in diffuse large B-cell lymphoma: Implications for anti-CD47 immunotherapy and prognostication.
    Br J Haematol. 2023 Dec 12. doi: 10.1111/bjh.19264.
    PubMed    


  29. FLOSPERGHER E, Marino F, Calimeri T, Cangi MG, et al
    Primary central nervous system marginal zone lymphoma.
    Br J Haematol. 2023 Dec 6. doi: 10.1111/bjh.19238.
    PubMed     Abstract available


  30. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    PubMed    


    November 2023
  31. SARTORI G, Tarantelli C, Spriano F, Gaudio E, et al
    The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19218.
    PubMed     Abstract available


  32. WATANABE T, Tobinai K, Wakabayashi M, Maruyama D, et al
    R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
    Br J Haematol. 2023 Nov 23. doi: 10.1111/bjh.19213.
    PubMed     Abstract available


  33. HEINI AD, Bacher U, Pabst T
    Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19195.
    PubMed     Abstract available


  34. CARACCIOLO D, Polera N, Belmonte B, Conforti F, et al
    UMG1/CD3epsilon-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19183.
    PubMed     Abstract available


  35. PEDERSEN MA, Gormsen LC, Jakobsen LH, Eyre TA, et al
    The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
    Br J Haematol. 2023 Nov 13. doi: 10.1111/bjh.19194.
    PubMed     Abstract available


  36. GALLI E, Bellesi S, Pansini I, Di Cesare G, et al
    The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
    Br J Haematol. 2023;203:564-570.
    PubMed     Abstract available


    October 2023
  37. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    PubMed     Abstract available


  38. STUVER R, Noy A, Vardhana SA, Zelenetz AD, et al
    Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19178.
    PubMed    


  39. MINSON A, Hamad N, Di Ciaccio P, Talaulikar D, et al
    Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
    Br J Haematol. 2023 Oct 30. doi: 10.1111/bjh.19179.
    PubMed     Abstract available


  40. GONG IY, Prica A, Ante Z, Calzavara A, et al
    Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
    Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166.
    PubMed     Abstract available


  41. RAMSOWER CA, Rosenthal A, Robetorye RS, Mwangi R, et al
    Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19153.
    PubMed     Abstract available


  42. EYRE TA, Bishton MJ, McCulloch R, O'Reilly M, et al
    Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19131.
    PubMed    


  43. CALABRETTA E, di Trani M, Corrado F, Sollini M, et al
    Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 18. doi: 10.1111/bjh.19162.
    PubMed     Abstract available


  44. BOYLE S, Roddie C, O'Reilly M, Menne T, et al
    Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
    Br J Haematol. 2023 Oct 17. doi: 10.1111/bjh.19157.
    PubMed     Abstract available


  45. KYVSGAARD ER, Riley C, Clausen MR, Harslof M, et al
    Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy.
    Br J Haematol. 2023 Oct 13. doi: 10.1111/bjh.19156.
    PubMed    


  46. MAMLOUK O, Strati P, Feng L, Sun R, et al
    Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19152.
    PubMed    


  47. CONTARINI G, Carraro E, Lovisa F, Martire G, et al
    Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19151.
    PubMed    


  48. LIU H, He Z, Gui R, Guo J, et al
    Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
    Br J Haematol. 2023 Oct 6. doi: 10.1111/bjh.19140.
    PubMed     Abstract available


  49. GAO J, Dahiya S, Patel SA
    Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Br J Haematol. 2023;203:161-168.
    PubMed     Abstract available


    September 2023
  50. LEWIS KL, Cheah CY
    Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
    Br J Haematol. 2023 Sep 24. doi: 10.1111/bjh.19095.
    PubMed    


  51. HAYASHI K, Koyama D, Sato Y, Fukatsu M, et al
    Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19.
    Br J Haematol. 2023 Sep 11. doi: 10.1111/bjh.19106.
    PubMed    


  52. LI H, Yuan L, Wang P, Sheng Y, et al
    Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
    Br J Haematol. 2023;202:1055-1060.
    PubMed    


  53. PROKOPH N, Matthews JD, Trigg RM, Montes-Mojarro IA, et al
    Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Br J Haematol. 2023;202:985-994.
    PubMed     Abstract available


  54. XIONG J, Zhao WL
    A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma.
    Br J Haematol. 2023 Sep 1. doi: 10.1111/bjh.19066.
    PubMed    


    August 2023
  55. ZHANG C, Mou B, Xu J, Wang J, et al
    Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.
    Br J Haematol. 2023 Aug 30. doi: 10.1111/bjh.19089.
    PubMed     Abstract available


  56. GAUTHIER M, Dombrowski D, Vergnolle I, Kfoury E, et al
    Vacuolated lymphocytes as initial presentation of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2023 Aug 23. doi: 10.1111/bjh.19030.
    PubMed    


  57. WATANABE M, Kanda J, Fukuda T, Uchida N, et al
    Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
    Br J Haematol. 2023 Aug 23. doi: 10.1111/bjh.19041.
    PubMed     Abstract available


  58. CHUNG EYL, Sartori G, Ponzoni M, Cascione L, et al
    ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
    Br J Haematol. 2023 Aug 16. doi: 10.1111/bjh.19018.
    PubMed     Abstract available


  59. RYAN CE, Zon RL, Redd R, Fisher DC, et al
    Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
    Br J Haematol. 2023 Aug 16. doi: 10.1111/bjh.19037.
    PubMed     Abstract available


  60. ZHOU L, Fu W, Wu S, Xu K, et al
    Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Br J Haematol. 2023;202:517-524.
    PubMed     Abstract available


  61. VITOLO U, Frascione PMM, Bonello F
    Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more?
    Br J Haematol. 2023;202:731-733.
    PubMed     Abstract available


  62. HE MY, Kayamori K
    Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.
    Br J Haematol. 2023;202:720-721.
    PubMed     Abstract available


  63. ROVSING AB, Thomsen EA, Nielsen I, Skov TW, et al
    Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28.
    Br J Haematol. 2023;202:825-839.
    PubMed     Abstract available


    July 2023
  64. JEFFREY A, Mason G, Kerridge I, Kumar P, et al
    Bone marrow pseudo-Gaucher cells demonstrating haemophagocytosis associated with extranodal NK/T cell lymphoma, nasal type.
    Br J Haematol. 2023 Jul 31. doi: 10.1111/bjh.18998.
    PubMed    


  65. KUITUNEN H, Puhakka I, Ronka A, Selander T, et al
    Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma.
    Br J Haematol. 2023 Jul 31. doi: 10.1111/bjh.19003.
    PubMed    


  66. CARLSEN ED, Aarabi M, Swerdlow SH
    Unexpected MYC::DMD translocation after transformation of follicular lymphoma with IGH::BCL2 and IGH::MYC.
    Br J Haematol. 2023 Jul 23. doi: 10.1111/bjh.18994.
    PubMed    


  67. MARTIN GARCIA-SANCHO A, Baile M, Rodriguez G, Dlouhy I, et al
    Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
    Br J Haematol. 2023 Jul 23. doi: 10.1111/bjh.18989.
    PubMed     Abstract available


  68. SULEMAN A, Aktar SJ, Ante Z, Liu N, et al
    Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
    Br J Haematol. 2023 Jul 20. doi: 10.1111/bjh.18972.
    PubMed     Abstract available


  69. GAO F, Liu H, Meng X, Liu J, et al
    Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
    Br J Haematol. 2023 Jul 16. doi: 10.1111/bjh.18974.
    PubMed     Abstract available


  70. SHIN J, Lee JY, Lee GW, Kim WS, et al
    Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.
    Br J Haematol. 2023 Jul 5. doi: 10.1111/bjh.18965.
    PubMed    


  71. WANG X, Wen L, Liao J, Feng Y, et al
    First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study.
    Br J Haematol. 2023 Jul 2. doi: 10.1111/bjh.18957.
    PubMed     Abstract available


  72. VAN THILLO Q, Dewaele B, De Bie J, Michaux L, et al
    Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion.
    Br J Haematol. 2023;202:e7-e10.
    PubMed    


  73. LV M, Liu L, He Y, Yang D, et al
    Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
    Br J Haematol. 2023;202:369-378.
    PubMed     Abstract available


  74. JO T, Yoshihara S, Okuyama Y, Fujii K, et al
    Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
    Br J Haematol. 2023;202:256-266.
    PubMed     Abstract available


  75. LAMURE S, Herbaux C
    Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL.
    Br J Haematol. 2023;202:217-218.
    PubMed    


  76. KITAMURA W, Asada N, Naoi Y, Abe M, et al
    Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy.
    Br J Haematol. 2023;202:294-307.
    PubMed     Abstract available


    June 2023
  77. MARTIN GARCIA-SANCHO A, Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, et al
    Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18941.
    PubMed     Abstract available


  78. MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
    Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
    PubMed     Abstract available


  79. WILSON MR, Haynes E, Parsons K, Hopkins D, et al
    'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma-A multicentre, retrospective study.
    Br J Haematol. 2023 Jun 25. doi: 10.1111/bjh.18947.
    PubMed     Abstract available


  80. TURNER R, Quach H, Horvath N, Kerridge I, et al
    Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
    Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
    PubMed     Abstract available


  81. ENTROP JP, Weibull CE, Smedby KE, Jakobsen LH, et al
    Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study.
    Br J Haematol. 2023 Jun 16. doi: 10.1111/bjh.18938.
    PubMed     Abstract available


  82. VUOLIO T, Kuittinen O, Vayrynen JP, Teppo HR, et al
    R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up.
    Br J Haematol. 2023 Jun 6. doi: 10.1111/bjh.18896.
    PubMed    


    May 2023
  83. PUCKRIN R, Owen C, Stewart D, Peters A, et al
    Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
    Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.
    PubMed    


  84. LIANG JH, Ren YM, Du KX, Gao R, et al
    MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma.
    Br J Haematol. 2023 May 24. doi: 10.1111/bjh.18878.
    PubMed     Abstract available


  85. LAURENT C, Flores M, Chartier L, Huet S, et al
    Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
    Br J Haematol. 2023 May 22. doi: 10.1111/bjh.18881.
    PubMed    


  86. STUVER R, Horwitz SM, Advani RH, Vose JM, et al
    Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
    Br J Haematol. 2023 May 22. doi: 10.1111/bjh.18885.
    PubMed     Abstract available


  87. MAROUF A, Molinari N, Sibon D, Cottereau AS, et al
    Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
    Br J Haematol. 2023 May 16. doi: 10.1111/bjh.18859.
    PubMed     Abstract available


  88. DUNS G, Winkle M, Chong L, Ennishi D, et al
    Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma.
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18870.
    PubMed    


  89. MCCULLOCH R
    Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18868.
    PubMed     Abstract available


  90. KAMBHAMPATI S, Shumilov E, Saumoy M, Herrera AF, et al
    Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
    Br J Haematol. 2023 May 15. doi: 10.1111/bjh.18869.
    PubMed     Abstract available


  91. CHIHARA D, Nastoupil LJ, Flowers CR
    Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives.
    Br J Haematol. 2023 May 11. doi: 10.1111/bjh.18861.
    PubMed     Abstract available


  92. WEI C, Wang W, Zhang Y, Zhao D, et al
    Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
    Br J Haematol. 2023 May 3. doi: 10.1111/bjh.18824.
    PubMed     Abstract available


  93. ATALLAH-YUNES SA, Salman O, Robertson MJ
    Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.
    Br J Haematol. 2023;201:383-395.
    PubMed     Abstract available


  94. NAGLER A, Perriello VM, Falini L, Falini B, et al
    How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Br J Haematol. 2023;201:396-410.
    PubMed     Abstract available


  95. WENNERAS C, Aranburu A, Wass L, Grankvist A, et al
    Infection with Neoehrlichia mikurensis promotes the development of malignant B-cell lymphomas.
    Br J Haematol. 2023;201:480-488.
    PubMed     Abstract available


    April 2023
  96. VOSE JM, Ganguly S, Bierman PJ, Bociek RG, et al
    Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
    Br J Haematol. 2023 Apr 25. doi: 10.1111/bjh.18821.
    PubMed     Abstract available


  97. KUHNL A, Kirkwood AA, Roddie C, Menne T, et al
    CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
    Br J Haematol. 2023 Apr 20. doi: 10.1111/bjh.18810.
    PubMed     Abstract available


  98. DUBNIKOV SHARON T, Assayag M, Avni B, Kfir-Erenfeld S, et al
    Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Apr 18. doi: 10.1111/bjh.18816.
    PubMed     Abstract available


  99. LE GOFF E, Blanc-Durand P, Roulin L, Lafont C, et al
    Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
    Br J Haematol. 2023 Apr 10. doi: 10.1111/bjh.18809.
    PubMed     Abstract available


  100. PUNNETT A, Baxter NN, Hodgson D, Sutradhar R, et al
    Treatment patterns and outcomes in adolescents and young adults with nodular lymphocyte-predominant Hodgkin lymphoma: an IMPACT cohort study.
    Br J Haematol. 2023 Apr 4. doi: 10.1111/bjh.18757.
    PubMed     Abstract available


  101. CAMPBELL BA, Brown R, Lambertini A, Hofman MS, et al
    Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Br J Haematol. 2023 Apr 4. doi: 10.1111/bjh.18644.
    PubMed     Abstract available


  102. BELDI-FERCHIOU A, Jais JP, Ghesquieres H, Casasnovas RO, et al
    Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
    Br J Haematol. 2023;201:256-266.
    PubMed     Abstract available


    March 2023
  103. GAZEAU N, Mitra S, Nudel M, Tilmont R, et al
    Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.
    Br J Haematol. 2023 Mar 31. doi: 10.1111/bjh.18775.
    PubMed    


  104. SHEN K, Yang C
    Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.
    PubMed    


  105. LANZA F, De Giorgio R, Zavagli G
    The oldest case of lymphoma? Insights from a XIII century fresco.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18750.
    PubMed    


  106. WENTZELL S, Morash B, Chang H
    Extensive histiocytosis masking anaplastic large-cell lymphoma (ALCL).
    Br J Haematol. 2023 Mar 23. doi: 10.1111/bjh.18730.
    PubMed    


  107. BRAVETTI C, Degaud M, Armand M, Sourdeau E, et al
    Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma.
    Br J Haematol. 2023 Mar 20. doi: 10.1111/bjh.18758.
    PubMed     Abstract available


  108. SHANKAR A, Bomanji J
    An illuminating piece in the jigsaw of Hodgkin lymphoma risk stratification.
    Br J Haematol. 2023 Mar 17. doi: 10.1111/bjh.18764.
    PubMed     Abstract available


  109. MILGROM SA, Kim J, Pei Q, Lee I, et al
    Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18734.
    PubMed     Abstract available


  110. GRUND J, Iben K, Reinke S, Buhnen I, et al
    Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
    Br J Haematol. 2023 Mar 15. doi: 10.1111/bjh.18762.
    PubMed     Abstract available


  111. ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
    Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.
    PubMed    


  112. DI CIACCIO PR, Mills G, Shipton MJ, Campbell B, et al
    The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.
    Br J Haematol. 2023 Mar 7. doi: 10.1111/bjh.18727.
    PubMed     Abstract available


  113. LIM KJC, Di Ciaccio P, Polizzotto MN, Milliken S, et al
    Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
    Br J Haematol. 2023 Mar 3. doi: 10.1111/bjh.18704.
    PubMed     Abstract available


    February 2023
  114. BELOT A, Camus V, Portugues C, Paget J, et al
    Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.
    Br J Haematol. 2023 Feb 22. doi: 10.1111/bjh.18705.
    PubMed     Abstract available


  115. WILSON MR, Barrett A, Cheah CY, Eyre TA, et al
    How I manage mantle cell lymphoma: indolent versus aggressive disease.
    Br J Haematol. 2023 Feb 20. doi: 10.1111/bjh.18697.
    PubMed     Abstract available


  116. CHAUBARD S, Marouf A, Lavergne D, Lemonnier F, et al
    Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
    Br J Haematol. 2023 Feb 17. doi: 10.1111/bjh.18689.
    PubMed     Abstract available


  117. ARENA A, Romeo MA, Focaccetti C, Anastasiadou E, et al
    Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma.
    Br J Haematol. 2023 Feb 12. doi: 10.1111/bjh.18688.
    PubMed    


  118. OSTROWSKA B, Domanska-Czyz K, Romejko-Jarosinska J, Osowiecki M, et al
    Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
    Br J Haematol. 2023 Feb 10. doi: 10.1111/bjh.18687.
    PubMed     Abstract available


  119. ARCARI A, Tabanelli V, Merli F, Marcheselli L, et al
    Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
    Br J Haematol. 2023 Feb 2. doi: 10.1111/bjh.18678.
    PubMed     Abstract available


  120. CHATTERJEE G, Patkar N
    United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Br J Haematol. 2023;200:277-279.
    PubMed     Abstract available


  121. IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
    Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Br J Haematol. 2023;200:381-384.
    PubMed    


  122. QUALLS D, Imber BS, Okwali M, Hamlin PA, et al
    Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
    Br J Haematol. 2023;200:524-527.
    PubMed    


    January 2023
  123. DEL TORO-MIJARES R, Oluwole O, Jayani RV, Kassim AA, et al
    Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Br J Haematol. 2023 Jan 29. doi: 10.1111/bjh.18656.
    PubMed     Abstract available


  124. KUNIMI K, Usui Y, Sugawara R, Asakage M, et al
    Clinical features of primary vitreoretinal lymphoma developing extra-central nervous system (CNS)/testicular lymphomas with or without CNS involvement: A single-centre study of 13 cases.
    Br J Haematol. 2023 Jan 24. doi: 10.1111/bjh.18663.
    PubMed    


  125. BAGAL B, Sarma R, Dey S, Nayak L, et al
    Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
    Br J Haematol. 2023 Jan 22. doi: 10.1111/bjh.18659.
    PubMed    


  126. PUCKRIN R, Chua N, Chin K, Peters A, et al
    Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma.
    Br J Haematol. 2023 Jan 10. doi: 10.1111/bjh.18640.
    PubMed     Abstract available


  127. WILSON J
    Pseudo-faggot cells in splenic marginal zone lymphoma.
    Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.
    PubMed    


  128. MORENO DF, Lopez-Guerra M, Paz S, Oliver-Caldes A, et al
    Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia.
    Br J Haematol. 2023;200:187-196.
    PubMed     Abstract available


    December 2022
  129. FIACCADORI V, Neven A, Fortpied C, Aurer I, et al
    Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
    Br J Haematol. 2022 Dec 21. doi: 10.1111/bjh.18594.
    PubMed     Abstract available


  130. SANOU N, Rozen L
    Lymphocytes in monkeypox infection mimicking T-cell lymphoma.
    Br J Haematol. 2022 Dec 16. doi: 10.1111/bjh.18589.
    PubMed    


  131. HARMANEN M, Hujo M, Sund R, Sorigue M, et al
    Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.
    Br J Haematol. 2022 Dec 13. doi: 10.1111/bjh.18597.
    PubMed     Abstract available


  132. SPRIANO F, Tarantelli C, Arribas AJ, Gaudio E, et al
    In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103.
    Br J Haematol. 2022 Dec 9. doi: 10.1111/bjh.18576.
    PubMed    


  133. CHENG CL, Yao CY, Huang PH, Yu CW, et al
    Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
    Br J Haematol. 2022 Dec 8. doi: 10.1111/bjh.18598.
    PubMed     Abstract available


  134. AFIFY Z, Orjuela-Grimm M, Smith CM, Dalal M, et al
    Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
    Br J Haematol. 2022 Dec 1. doi: 10.1111/bjh.18498.
    PubMed     Abstract available


    November 2022
  135. ATMAJA B, Millard T, Wotherspoon A, Attygalle AD, et al
    A rare case of primary cutaneous-anaplastic large cell lymphoma (PC-ALCL) localized to the eyelid.
    Br J Haematol. 2022 Nov 29. doi: 10.1111/bjh.18573.
    PubMed    


  136. CWYNARSKI K, Cummin T, Osborne W, Lewis J, et al
    Management of secondary central nervous system lymphoma.
    Br J Haematol. 2022 Nov 21. doi: 10.1111/bjh.18539.
    PubMed    


  137. SHAH H, Jang H, Kim S, Halwani AS, et al
    A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race.
    Br J Haematol. 2022 Nov 18. doi: 10.1111/bjh.18564.
    PubMed     Abstract available


  138. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
    PubMed    


  139. SENGAR M, Jain H, Shet T, Sridhar E, et al
    Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
    Br J Haematol. 2022 Nov 2. doi: 10.1111/bjh.18532.
    PubMed     Abstract available


  140. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    PubMed     Abstract available


    October 2022
  141. SAIZ LC, Leache L, Gutierrez-Valencia M, Erviti J, et al
    Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18505.
    PubMed    


  142. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Oct 25. doi: 10.1111/bjh.18506.
    PubMed    


  143. MUNTANOLA A, Mozas P, Mercadal S, Huguet M, et al
    Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18522.
    PubMed     Abstract available


  144. KNORR F, Woessmann W
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma-Response.
    Br J Haematol. 2022 Oct 19. doi: 10.1111/bjh.18528.
    PubMed    


  145. HESS G, Dreyling M, Oberic L, Gine E, et al
    Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
    Br J Haematol. 2022 Oct 18. doi: 10.1111/bjh.18519.
    PubMed     Abstract available


  146. BERTINCHAMP R, Garzaro M, Boutboul D, Galicier L, et al
    Mantle cell lymphoma in human immunodeficiency virus-infected patients.
    Br J Haematol. 2022 Oct 12. doi: 10.1111/bjh.18493.
    PubMed    


  147. CHEN M, Ouyang F, Wu T, Hu Y, et al
    Remission of extranodal NK/T-cell lymphoma, nasal type, after SARS-CoV-2 vaccination.
    Br J Haematol. 2022 Oct 5. doi: 10.1111/bjh.18496.
    PubMed    


  148. AGARWAL G, Moule S, Cope A, Maudgil D, et al
    Spontaneous splenic rupture as initial presentation of diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Oct 3. doi: 10.1111/bjh.18471.
    PubMed    


  149. SMITH OP
    Denis Burkitt: A cancer, the virus and the prevention of man-made diseases.
    Br J Haematol. 2022;199:297.
    PubMed    


    September 2022
  150. ZIJTREGTOP EAM, Diez C, Zwaan CM, Veening MA, et al
    Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
    Br J Haematol. 2022 Sep 20. doi: 10.1111/bjh.18473.
    PubMed     Abstract available


  151. GISSELBRECHT C, Sibon D
    Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous stem cell transplant?
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18468.
    PubMed     Abstract available


  152. FURQAN F, Ahn KW, Chen Y, Kaur M, et al
    Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
    Br J Haematol. 2022 Sep 19. doi: 10.1111/bjh.18467.
    PubMed     Abstract available


  153. CHERNG HJ, Xu G, Feng L, Steiner R, et al
    Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
    Br J Haematol. 2022 Sep 6. doi: 10.1111/bjh.18441.
    PubMed     Abstract available


  154. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    PubMed     Abstract available


  155. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    PubMed     Abstract available


  156. DHOLARIA B, Mehraban N, Baer B, Long N, et al
    Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
    Br J Haematol. 2022;198:1073-1075.
    PubMed    


    August 2022
  157. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    PubMed     Abstract available


  158. LIM SH
    COVID-19 infection in primary central nervous system lymphoma treatment: Who is most at risk?
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18416.
    PubMed    


  159. RAJAMAKI A, Hujo M, Sund R, Prusila REI, et al
    Link between disease status at 24 months and mortality in follicular lymphoma.
    Br J Haematol. 2022 Aug 26. doi: 10.1111/bjh.18423.
    PubMed    


  160. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    PubMed     Abstract available


  161. BINKLEY MS
    Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 22. doi: 10.1111/bjh.18406.
    PubMed     Abstract available


  162. NAIK A, Gooley T, Loeb K, Soma L, et al
    The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment.
    Br J Haematol. 2022 Aug 16. doi: 10.1111/bjh.18404.
    PubMed     Abstract available


  163. JESSA R, Chien N, Villa D, Freeman CL, et al
    Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
    Br J Haematol. 2022 Aug 12. doi: 10.1111/bjh.18399.
    PubMed     Abstract available


  164. STEFFANONI S, Calimeri T, Laurenge A, Fox CP, et al
    Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
    Br J Haematol. 2022 Aug 9. doi: 10.1111/bjh.18396.
    PubMed     Abstract available


  165. TARANTELLI C, Bertoni F
    United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Aug 2. doi: 10.1111/bjh.18384.
    PubMed     Abstract available


  166. ROSLER W, Zenz T
    GOALs in relapsed DLBCL.
    Br J Haematol. 2022;198:419-420.
    PubMed    


    July 2022
  167. O'REILLY MA, Sanderson R, Wilson W, Iyengar S, et al
    Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapse
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18378.
    PubMed    


  168. WEINSTOCK M, Elavalakanar P, Bright S, Ambati SR, et al
    Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Br J Haematol. 2022 Jul 27. doi: 10.1111/bjh.18383.
    PubMed     Abstract available


  169. HARTMANN S, Soltani AS, Bankov K, Bein J, et al
    Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2022 Jul 26. doi: 10.1111/bjh.18376.
    PubMed     Abstract available


  170. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    PubMed     Abstract available


  171. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
    PubMed    


  172. DU W, Estalilla OC, Jelic TM, Hayes JD, et al
    Bone marrow involvement by breast implant-associated anaplastic large cell lymphoma.
    Br J Haematol. 2022 Jul 14. doi: 10.1111/bjh.18364.
    PubMed    


  173. PICARDI M, Giordano C, Pugliese N, Esposito M, et al
    Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
    Br J Haematol. 2022 Jul 12. doi: 10.1111/bjh.18348.
    PubMed     Abstract available


    June 2022
  174. SHARGIAN L, Raanani P, Yeshurun M, Gafter-Gvili A, et al
    Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18335.
    PubMed     Abstract available


  175. KAWASAKI N, Nishito Y, Yoshimura Y, Yoshiura S, et al
    The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Jun 28. doi: 10.1111/bjh.18341.
    PubMed     Abstract available


  176. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    PubMed    


  177. MIAN A, Bhattarai N, Sheu M, Ondrejka SL, et al
    Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
    Br J Haematol. 2022 Jun 22. doi: 10.1111/bjh.18333.
    PubMed    


  178. KAJI FA, Martinez-Calle N, Sovani V, Fox CP, et al
    Rare central nervous system lymphomas.
    Br J Haematol. 2022;197:662-678.
    PubMed     Abstract available


    May 2022
  179. STRUSSMANN T, Glatzki F, Engelhardt M, Mertelsmann R, et al
    Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.
    Br J Haematol. 2022 May 27. doi: 10.1111/bjh.18280.
    PubMed    


  180. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available


  181. DAWUDI Y, Benali K, Beydon M, Hourseau M, et al
    B-cell lymphoma mimicking relapsing polychondritis.
    Br J Haematol. 2022 May 20. doi: 10.1111/bjh.18220.
    PubMed    


  182. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available


  183. ARMITAGE JO, Gale RP, Jaffe ES
    Lymphoma Nomenclature - What's in a name?
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18063.
    PubMed    


  184. MOMOTOW J, Buhnen I, Trautmann-Grill K, Kobbe G, et al
    Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
    Br J Haematol. 2022 May 11. doi: 10.1111/bjh.18231.
    PubMed    


  185. DITTUS C, Miller JA, Wehbie R, Castillo JJ, et al
    Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
    Br J Haematol. 2022 May 4. doi: 10.1111/bjh.18228.
    PubMed    


  186. DIXON JG, Dimier N, Nielsen T, Zheng J, et al
    End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
    Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18217.
    PubMed     Abstract available


  187. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available


    April 2022
  188. KUHNL A, Roddie C, Kirkwood AA, Tholouli E, et al
    A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Br J Haematol. 2022 Apr 29. doi: 10.1111/bjh.18209.
    PubMed     Abstract available


  189. CALABRETTA E, Guidetti A, Ricci F, Di Trani M, et al
    Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18183.
    PubMed     Abstract available


  190. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
    Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
    Br J Haematol. 2022 Apr 25. doi: 10.1111/bjh.18197.
    PubMed     Abstract available


  191. TANIGUCHI T, Nakayama S, Tanaka H, Rai S, et al
    Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.
    Br J Haematol. 2022 Apr 22. doi: 10.1111/bjh.18208.
    PubMed     Abstract available


  192. MANSON G, Herbaux C, Schiano JM, Casasnovas O, et al
    Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol. 2022 Apr 21. doi: 10.1111/bjh.18198.
    PubMed    


  193. EL-GALALY TC, Glimelius I
    Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
    Br J Haematol. 2022 Apr 19. doi: 10.1111/bjh.18199.
    PubMed     Abstract available


  194. ETHIRAJ P, Sasi B, Holder KN, Lin AP, et al
    Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1alpha intersect to regulate angiogenesis in B-cell lymphoma.
    Br J Haematol. 2022 Apr 12. doi: 10.1111/bjh.18196.
    PubMed     Abstract available


  195. ANDERSEN MD, Hamilton-Dutoit S, Modvig L, Vase M, et al
    Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
    Br J Haematol. 2022 Apr 8. doi: 10.1111/bjh.18180.
    PubMed     Abstract available


  196. EKELS A, van de Poll-Franse LV, Posthuma EFM, Kieffer J, et al
    Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
    Br J Haematol. 2022 Apr 2. doi: 10.1111/bjh.18139.
    PubMed     Abstract available


  197. SHANKAR A, Hall GW, McKay P, Gallop-Evans E, et al
    Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18169.
    PubMed     Abstract available


  198. HESS G, Huttmann A, Witzens-Harig M, Dreyling MH, et al
    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18161.
    PubMed     Abstract available


  199. PASZKIEWICZ-KOZIK E, Michalski W, Taszner M, Mordak-Domagala M, et al
    Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2022 Apr 1. doi: 10.1111/bjh.18166.
    PubMed     Abstract available


  200. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available


  201. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available


    March 2022
  202. TERAS LR, Bertrand KA, Deubler EL, Chao CR, et al
    Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.
    Br J Haematol. 2022 Mar 29. doi: 10.1111/bjh.18150.
    PubMed     Abstract available


  203. MERCADAL S, Alana M, Barcelo MI, Bruixola G, et al
    Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
    Br J Haematol. 2022 Mar 20. doi: 10.1111/bjh.18148.
    PubMed    


  204. GHOLIHA AR, Hollander P, Lof L, Glimelius I, et al
    Checkpoint CD47 expression in classical Hodgkin lymphoma.
    Br J Haematol. 2022 Mar 17. doi: 10.1111/bjh.18137.
    PubMed     Abstract available


  205. BROCKELMANN PJ, Borchmann P
    Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.
    Br J Haematol. 2022 Mar 9. doi: 10.1111/bjh.18130.
    PubMed    


  206. RIISE J, Meyer S, Blaas I, Chopra A, et al
    Rituximab-treated lymphoma patients develop strong CD8 T-cell responses following COVID-19 vaccination.
    Br J Haematol. 2022 Mar 7. doi: 10.1111/bjh.18149.
    PubMed     Abstract available


  207. EYRE TA, Jensen P, Booth S, El-Galaly TC, et al
    Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.
    Br J Haematol. 2022 Mar 2. doi: 10.1111/bjh.18104.
    PubMed     Abstract available


  208. PALLETT SJC, Wake R, Youngs J, Pope C, et al
    Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
    Br J Haematol. 2022;196:1170-1174.
    PubMed    


    February 2022
  209. FOLLOWS GA, Barrington SF, Bhuller KS, Culligan DJ, et al
    Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
    Br J Haematol. 2022 Feb 22. doi: 10.1111/bjh.18083.
    PubMed     Abstract available


  210. ROY I, Smilnak G, Burkart M, Hamilton E, et al
    Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2022 Feb 9. doi: 10.1111/bjh.18054.
    PubMed     Abstract available


  211. SAVANI M, Ahn KW, Chen Y, Ahmed S, et al
    Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
    Br J Haematol. 2022 Feb 2. doi: 10.1111/bjh.18052.
    PubMed     Abstract available


  212. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available


    January 2022
  213. AVIVI I, Luttwak E, Saiag E, Halperin T, et al
    BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.
    Br J Haematol. 2022 Jan 25. doi: 10.1111/bjh.18029.
    PubMed     Abstract available


  214. EL-GALALY TC, Villa D, Cheah CY, Gormsen LC, et al
    Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Br J Haematol. 2022 Jan 17. doi: 10.1111/bjh.18016.
    PubMed     Abstract available


  215. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    PubMed    


  216. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    PubMed    


  217. EL-MALLAWANY NK, Curry CV, Allen CE
    Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    Br J Haematol. 2022;196:31-44.
    PubMed     Abstract available


    December 2021
  218. HAEBE S, Keay W, Alig S, Mohr AW, et al
    The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.
    Br J Haematol. 2021 Dec 29. doi: 10.1111/bjh.17990.
    PubMed     Abstract available


  219. REN YM, Shang CY, Liang JH, Yin H, et al
    Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma.
    Br J Haematol. 2021 Dec 28. doi: 10.1111/bjh.18000.
    PubMed     Abstract available


  220. BRANDEFORS L, Sander B, Lundqvist K, Kimby E, et al
    Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Br J Haematol. 2021 Dec 27. doi: 10.1111/bjh.18002.
    PubMed     Abstract available


  221. CHIAPPELLA A, Diop F, Agostinelli C, Novo M, et al
    Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
    Br J Haematol. 2021 Dec 23. doi: 10.1111/bjh.17971.
    PubMed     Abstract available


  222. KREISSL S, Voltin CA, Kaul H, Buhnen I, et al
    Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2021 Dec 20. doi: 10.1111/bjh.17997.
    PubMed    


  223. MOLETI ML, Testi AM, Foa R
    Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
    Br J Haematol. 2021 Dec 6. doi: 10.1111/bjh.17979.
    PubMed     Abstract available


    November 2021
  224. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    PubMed    


  225. ZHU Y, Tian S, Xu L, Ma Y, et al
    GELAD chemotherapy with sandwiched radiotherapy for patients with newly diagnosed stage IE/IIE natural killer/T-cell lymphoma: a prospective multicentre study.
    Br J Haematol. 2021 Nov 21. doi: 10.1111/bjh.17960.
    PubMed     Abstract available


  226. GILLESSEN S, Huttmann A, Vucinic V, Muller H, et al
    Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Gro
    Br J Haematol. 2021 Nov 14. doi: 10.1111/bjh.17878.
    PubMed     Abstract available


  227. GUTIERREZ-GARCIA G, Martinez C, Boumendil A, Finel H, et al
    Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17939.
    PubMed     Abstract available


  228. BANERJEE R, Midha S, Kelkar AH, Goodman A, et al
    Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Nov 8. doi: 10.1111/bjh.17945.
    PubMed    


  229. URBAN R, Chow R, Pickles T, Chan M, et al
    The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma.
    Br J Haematol. 2021 Nov 4. doi: 10.1111/bjh.17684.
    PubMed    


  230. LEONCINI L
    Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.
    Br J Haematol. 2021 Nov 2. doi: 10.1111/bjh.17922.
    PubMed    


  231. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


  232. KAJI D, Kusakabe M, Sakata-Yanagimoto M, Makishima K, et al
    Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
    Br J Haematol. 2021;195:585-594.
    PubMed     Abstract available


  233. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    PubMed    


    October 2021
  234. ZHANG S, Zhang T, Liu H, Zhao J, et al
    Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Br J Haematol. 2021 Oct 19. doi: 10.1111/bjh.17894.
    PubMed     Abstract available


  235. HALLIGAN SJ, Grainge MJ, Martinez-Calle N, Fox CP, et al
    Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Br J Haematol. 2021 Oct 18. doi: 10.1111/bjh.17896.
    PubMed     Abstract available


  236. BROCKELMANN PJ
    Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?
    Br J Haematol. 2021 Oct 14. doi: 10.1111/bjh.17891.
    PubMed    


  237. MOORE DC, Soni AC, Hu B, Smith ET, et al
    Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Br J Haematol. 2021 Oct 12. doi: 10.1111/bjh.17886.
    PubMed    


  238. DLOUHY I, Karube K, Enjuanes A, Salaverria I, et al
    Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17858.
    PubMed     Abstract available


  239. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available


  240. ZHANG YC, Wang JN, Ma SY, Cai J, et al
    Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 7. doi: 10.1111/bjh.17849.
    PubMed     Abstract available


  241. RICHTER J, John K, Staiger AM, Rosenwald A, et al
    Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
    Br J Haematol. 2021 Oct 6. doi: 10.1111/bjh.17874.
    PubMed     Abstract available


  242. AMAADOR K, Kersten MJ, Visser O, Brink M, et al
    Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2021 Oct 3. doi: 10.1111/bjh.17856.
    PubMed     Abstract available


  243. GUPTA S, Alexander S, Pole JD, Sutradhar R, et al
    Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2021 Oct 1. doi: 10.1111/bjh.17862.
    PubMed     Abstract available


  244. RUDZKI Z, Starczynski J, Dowds J, Pemberton N, et al
    In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.
    Br J Haematol. 2021;195:154.
    PubMed    


  245. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available


    September 2021
  246. TOPP MS, van Meerten T, Houot R, Minnema MC, et al
    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Sep 29. doi: 10.1111/bjh.17673.
    PubMed     Abstract available


  247. RIEDELL PA, Hamadani M, Ahn KW, Litovich C, et al
    Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
    Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865.
    PubMed     Abstract available


  248. LIU W, Chen X, Fan J, Zhu M, et al
    Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Br J Haematol. 2021 Sep 16. doi: 10.1111/bjh.17729.
    PubMed    


  249. GERHARD-HARTMANN E, Goergen H, Brockelmann PJ, Mottok A, et al
    9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17793.
    PubMed     Abstract available


  250. BASTIDAS-MORA G, Bea S, Navarro A, Gine E, et al
    Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
    Br J Haematol. 2021 Sep 14. doi: 10.1111/bjh.17815.
    PubMed     Abstract available


  251. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    PubMed    


  252. LUTFI F, Holtzman NG, Kansagra AJ, Mustafa Ali M, et al
    The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17738.
    PubMed     Abstract available


  253. BORCHMANN S
    Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17796.
    PubMed    


  254. HODSON DJ
    Diffuse large B-cell lymphoma genetics - simplifying the subtyping.
    Br J Haematol. 2021 Sep 7. doi: 10.1111/bjh.17803.
    PubMed    


  255. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available



  256. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    PubMed    


    August 2021
  257. MORIN RD, Arthur SE, Hodson DJ
    Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17811.
    PubMed     Abstract available


  258. LADDAGA FE, Masciopinto P, Nardelli C, Vacca MP, et al
    In male Hodgkin lymphoma patients, impaired fertility may be improved by non-gonadotoxic therapy.
    Br J Haematol. 2021 Aug 31. doi: 10.1111/bjh.17767.
    PubMed     Abstract available


  259. MARTINEZ-CALLE N, Isbell LK, Cwynarski K, Schorb E, et al
    Advances in treatment of elderly primary central nervous system lymphoma.
    Br J Haematol. 2021 Aug 26. doi: 10.1111/bjh.17799.
    PubMed     Abstract available


  260. FJORDEN K, Ekberg S, Kuric N, Smedby KE, et al
    Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
    Br J Haematol. 2021 Aug 25. doi: 10.1111/bjh.17792.
    PubMed    


  261. NOGUCHI K, Ikawa Y, Takenaka M, Sakai Y, et al
    Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Br J Haematol. 2021 Aug 22. doi: 10.1111/bjh.17776.
    PubMed    


  262. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  263. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available


  264. EICHENAUER DA, Buhnen I, Kreissl S, Goergen H, et al
    Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17770.
    PubMed     Abstract available


  265. MISHINA T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, et al
    Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.
    Br J Haematol. 2021 Aug 10. doi: 10.1111/bjh.17765.
    PubMed     Abstract available


  266. KESAVAN M, Zammar G, McQuillan JT, Macdonald WBG, et al
    Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17758.
    PubMed    


  267. KAJI FA, Martinez-Calle N, Bishton MJ, Figueroa R, et al
    Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Br J Haematol. 2021 Aug 8. doi: 10.1111/bjh.17747.
    PubMed     Abstract available


  268. CASTILLO JJ, LaMacchia J, Flynn CA, Sarosiek S, et al
    Plasmablastic lymphoma transformation in a patient with Waldenstrom macroglobulinemia treated with ibrutinib.
    Br J Haematol. 2021 Aug 6. doi: 10.1111/bjh.17759.
    PubMed    


  269. LANDSBURG DJ, Barta SK, Ramchandren R, Batlevi C, et al
    Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
    Br J Haematol. 2021 Aug 2. doi: 10.1111/bjh.17730.
    PubMed     Abstract available


  270. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


  271. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    PubMed    


  272. CORDOBA R, Luminari S, Eyre TA
    The use of frailty assessments in treating older adults with aggressive lymphomas.
    Br J Haematol. 2021;194:677-685.
    PubMed     Abstract available


    July 2021
  273. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available


  274. LYU R, Wang T, Wang Y, Xiong W, et al
    Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17703.
    PubMed     Abstract available


  275. RINALDI F, Marchesi F, Palombi F, Pelosi A, et al
    MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2021 Jul 28. doi: 10.1111/bjh.17734.
    PubMed     Abstract available


  276. ALCOCEBA M, Garcia-Alvarez M, Chillon MC, Jimenez C, et al
    Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
    Br J Haematol. 2021 Jul 27. doi: 10.1111/bjh.17719.
    PubMed     Abstract available


  277. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available


  278. OLUWOLE OO, Bouabdallah K, Munoz J, De Guibert S, et al
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17527.
    PubMed     Abstract available


  279. CHAPMAN JR, Bouska AC, Zhang W, Alderuccio JP, et al
    EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
    Br J Haematol. 2021 Jul 17. doi: 10.1111/bjh.17708.
    PubMed     Abstract available


  280. OHKI K, Kiyokawa N, Watanabe S, Iwafuchi H, et al
    Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
    Br J Haematol. 2021 Jul 13. doi: 10.1111/bjh.17639.
    PubMed     Abstract available


  281. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available


  282. HARADA T, Iwasaki H, Muta T, Urata S, et al
    Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Br J Haematol. 2021;194:101-110.
    PubMed     Abstract available


    June 2021
  283. BUSSOT L, Chevalier S, Cristante J, Grange B, et al
    Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
    Br J Haematol. 2021 Jun 21. doi: 10.1111/bjh.17550.
    PubMed     Abstract available


  284. YUE LM, Chau D, Kwong YL, Tse E, et al
    Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
    Br J Haematol. 2021 Jun 13. doi: 10.1111/bjh.17581.
    PubMed    


  285. SIMA A, Hollander P, Baecklund E, Smedby KE, et al
    Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17577.
    PubMed     Abstract available


  286. KOWA JY, Millard T, Goldman A, Sharma RK, et al
    Are treatment response assessment maps (TRAMs) and (18) F-choline positron emission tomography the future of central nervous system lymphoma imaging?
    Br J Haematol. 2021 Jun 9. doi: 10.1111/bjh.17632.
    PubMed    


  287. SABATINI PJB, Tremblay-LeMay RMA, Ahmadi Moghaddam P, Delabie JMA, et al
    Marginal zone lymphoma transdifferentiated to histiocytic sarcoma.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17582.
    PubMed    


  288. RUMMEL MJ, Janssens A, MacDonald D, Keating MM, et al
    A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
    Br J Haematol. 2021;193:1123-1133.
    PubMed     Abstract available


  289. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  290. LAKHOTIA R, Roschewski M
    Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Br J Haematol. 2021;193:867-881.
    PubMed     Abstract available


    May 2021
  291. LEE S, Fujita K, Morishita T, Oiwa K, et al
    Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 26. doi: 10.1111/bjh.17554.
    PubMed     Abstract available


  292. GENUARDI E, Romano G, Beccuti M, Alessandria B, et al
    Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Br J Haematol. 2021 May 18. doi: 10.1111/bjh.17519.
    PubMed     Abstract available


  293. SETHI TK, Montanari F, Foss F, Reddy N, et al
    How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sezary syndrome.
    Br J Haematol. 2021 May 14. doi: 10.1111/bjh.17458.
    PubMed     Abstract available


  294. RAMPOTAS A, Wilson MR, Lomas O, Denny N, et al
    Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17513.
    PubMed     Abstract available


  295. HENTRICH M, Muller M, Wyen C, Bogner J, et al
    Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study.
    Br J Haematol. 2021 May 7. doi: 10.1111/bjh.17515.
    PubMed    


  296. ABU SABAA A, Morth C, Hasselblom S, Hedstrom G, et al
    Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
    Br J Haematol. 2021 May 5. doi: 10.1111/bjh.17206.
    PubMed     Abstract available


  297. WANG C, Althof PA, Bi C, Zhang W, et al
    A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17255.
    PubMed    


  298. BALASUBRAMANIAN S, Wang S, Major C, Hodkinson B, et al
    Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP +/- ibrutinib.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17450.
    PubMed     Abstract available


  299. MA SY, Tian XP, Cai J, Su N, et al
    A prognostic immune risk score for diffuse large B-cell lymphoma.
    Br J Haematol. 2021 May 3. doi: 10.1111/bjh.17478.
    PubMed     Abstract available


  300. CHIRON D
    Towards ecosystem integration for a better understanding of aggressiveness of B-cell lymphomas.
    Br J Haematol. 2021;193:447-448.
    PubMed    


    April 2021
  301. LAPENA-RODRIGUEZ M, Garces-Albir M, Gadea-Mateo R, Mata-Cano D, et al
    Multiple small bowel perforations during the treatment of primary intestinal extranodal natural killer/T-cell lymphoma, nasal type.
    Br J Haematol. 2021 Apr 29. doi: 10.1111/bjh.17229.
    PubMed    


  302. HABOT-WILNER Z, Frenkel S, Pe'er J
    Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Br J Haematol. 2021 Apr 26. doi: 10.1111/bjh.17451.
    PubMed     Abstract available


  303. KHURANA A, Maurer MJ
    Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17433.
    PubMed    


  304. LOH Z, Salvaris R, Chong G, Churilov L, et al
    Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
    Br J Haematol. 2021 Apr 14. doi: 10.1111/bjh.17436.
    PubMed     Abstract available


  305. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  306. OVERWEEL AFP, Budel LM, Sandberg Y
    Cutaneous blastoid mantle cell lymphoma.
    Br J Haematol. 2021 Apr 5. doi: 10.1111/bjh.17452.
    PubMed    


  307. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  308. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  309. POLVERELLI N, Elli EM, Abruzzese E, Palumbo GA, et al
    Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Br J Haematol. 2021;193:356-368.
    PubMed     Abstract available


    March 2021
  310. CONDOM M, Climent F, Fernandez D, Colomer D, et al
    Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience.
    Br J Haematol. 2021;192:1020-1025.
    PubMed     Abstract available


    February 2021
  311. MIKHAEEL NG, Cunningham D, Counsell N, McMillan A, et al
    FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Br J Haematol. 2021;192:504-513.
    PubMed     Abstract available


    January 2021
  312. RODRIGUEZ-PINILLA SM, Domingo-Domenech E, Climent F, Sanchez J, et al
    Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
    Br J Haematol. 2021;192:82-99.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.